CanSino leads HK-listed vaccine makers lower as BioNTech halts mRNA trial

Merck & Co

31/08/2026 06:10

** CanSino Biologics Hong Kong stock 6185.HK leads slide in HK-listed shares of Chinese vaccine makers after news that BioNTech 22UAy.DE halts mRNA colorectal cancer vaccine trial following safety review 
** CanSino's HK shares drop 8.6% to HK$29.02 and Shanghai shares 688185.SS fall 9.4% to 75.08 yuan
** BioNTech said it will end a mid-stage study of its experimental mRNA cancer vaccine after an independent committee found the treatment was unlikely to help colorectal cancer patients live longer, sending the company's U.S. shares down on Friday
** BioNTech's trial failure comes days after Merck MRK.N and Moderna MRNA.O said their mRNA-based vaccine helped prevent return and spread of melanoma in a trial; the success had raised hopes for similar mRNA-based vaccines
** Shares of Sino Biopharmaceutical 1177.HK, Genscript Biotech 1548.HK, Innovent Biologics 1801.HK, WuXi Biologics 2269.HK and Akeso Inc 9926.HK fall between 3.3% and 5.4% 
** China's CSI Vaccine and Biotech Index .CSI931992 drops 3.1%, while Hong Kong's Hang Seng Biotech Index .HSBIO eases 4.4%, Hang Seng Innovative Drug Index .HSIDI declines 4.6%


 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))